Esperion Therapeutics (United States)
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Esperion Therapeutics (United States), United States, covering academic research published from 2000 to 2023. Read More.
Open Access Percentage
53%
Total
Publications
150
Total Open
Publications
79
Total
Citations
9.8K
Open Access
Percentage
53%
Total
Publications
150
Total Open
Publications
79
Total
Citations
9.8K
Breakdown
Publisher Open
23%
Both
25%
Other Platform Open
5%
Closed
47%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 18%
13
Hybrid 61%
43
No Guarantees 21%
15
Other Platform Open
Domain 76%
34
Other Internet 20%
9
Institution 18%
8
Preprint 11%
5
Public 2%
1
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 34 |
Europe PMC | Domain | 18 |
DOI | Other Internet | 4 |
medRxiv | Preprint | 3 |
Universita Degli Studi Di Milano - Archivio Istituzionale della Ricerca | Institution | 2 |
Imperial College London - Spiral | Institution | 2 |
HAL | Other Internet | 2 |
bioRxiv | Preprint | 2 |
Washington University School of Medicine - Digital Commons@Becker | Institution | 1 |
UWA - UWA Profiles and Research Repository | Other Internet | 1 |